119 418

Cited 22 times in

Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).

DC Field Value Language
dc.contributor.authorKim, HR-
dc.contributor.authorJung, KH-
dc.contributor.authorIm, SA-
dc.contributor.authorIm, YH-
dc.contributor.authorKang, SY-
dc.contributor.authorPark, KH-
dc.contributor.authorLee, S-
dc.contributor.authorKim, SB-
dc.contributor.authorLee, KH-
dc.contributor.authorAhn, JS-
dc.contributor.authorKim, SI-
dc.contributor.authorSohn, JH-
dc.date.accessioned2014-05-21T01:45:47Z-
dc.date.available2014-05-21T01:45:47Z-
dc.date.issued2013-
dc.identifier.issn0923-7534-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/10049-
dc.description.abstractBACKGROUND: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer.



PATIENTS AND METHODS: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-negative, stage II/III breast cancer received six cycles of 75 mg/m(2) docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN).



RESULTS: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery.



CONCLUSIONS: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntibodies, Monoclonal, Humanized/administration & dosage-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/*administration & dosage-
dc.subject.MESHBreast Neoplasms/*drug therapy/epidemiology/*surgery-
dc.subject.MESHCarboplatin/administration & dosage-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy/*methods-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHTaxoids/administration & dosage-
dc.subject.MESHTreatment Outcome-
dc.titleMulticentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).-
dc.typeArticle-
dc.identifier.pmid23380385-
dc.identifier.urlhttp://annonc.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=23380385-
dc.contributor.affiliatedAuthor강, 석윤-
dc.type.localJournal Papers-
dc.identifier.doi10.1093/annonc/mds658-
dc.citation.titleAnnals of oncology : official journal of the European Society for Medical Oncology-
dc.citation.volume24-
dc.citation.number6-
dc.citation.date2013-
dc.citation.startPage1485-
dc.citation.endPage1490-
dc.identifier.bibliographicCitationAnnals of oncology : official journal of the European Society for Medical Oncology, 24(6):1485-1490, 2013-
dc.identifier.eissn1569-8041-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse